Emergence of Non-albicans Candida Species and Antifungal Resistance in a Tertiary Care Hospital
Open Access
- 28 December 2005
- journal article
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 58 (6) , 344-348
Abstract
The spectrum of candidiasis has changed with the emergence of non-albicans Candida spp. and acquired antifungal resistance, especially in immunocompromised hosts. This changing scenario has necessitated routine antifungal susceptibility testing. In the present work, 102 Candida spp. isolates gathered during 2003 - 2004 were characterized by standard procedures, and antifungal susceptibility testing to amphotericin B, fluconazole and itraconazole was performed by broth macrodilution (BMD)-minimum inhibitory concentration (MIC) and disk diffusion (DD) methods. Among all isolates, 77.4% were from an ICU and 10.8% were obtained from a nursery. The majority of the isolates were C. tropicalis (48%), followed by C. parapsilosis (27.4%) and C. albicans (22.5%). Overall 6.9, 4.9 and 3.9% of all isolates were resistant to amphotericin B, fluconazole and itraconazole, respectively. Out of the 5 (4.9%) isolates resistant to fluconazole, 4 (3.9%) were from patients with AIDS on fluconazole prophylaxis. A discrepancy was observed between the results of susceptibility testing by DD and those by BMD-MIC: 15 (14.7%) isolates were reported to be resistant by DD despite having low MICs. Based on these results, it was concluded that initial antifungal screening of clinical isolates by the DD method followed by confirmation of resistant strains by the broth dilution method is desirable to optimize patient management.Keywords
This publication has 16 references indexed in Scilit:
- Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002Diagnostic Microbiology and Infectious Disease, 2005
- Correlation between E-Test, Disk Diffusion, and Microdilution Methods for Antifungal Susceptibility Testing of Fluconazole and VoriconazoleAntimicrobial Agents and Chemotherapy, 2003
- Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patientsJournal of Antimicrobial Chemotherapy, 2002
- Prophylactic Antifungal Therapy in the Intensive Care UnitClinical Infectious Diseases, 2001
- Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998Antimicrobial Agents and Chemotherapy, 2000
- Candidemia in Allogeneic Blood and Marrow Transplant Recipients: Evolution of Risk Factors after the Adoption of Prophylactic FluconazoleThe Journal of Infectious Diseases, 2000
- The Epidemiology of Candidemia in Two United States Cities: Results of a Population-Based Active SurveillanceClinical Infectious Diseases, 1999
- The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceThe American Journal of Medicine, 1996
- CLINICAL SIGNIFICANCE OF CANDIDA ISOLATED FROM PERITONEUM IN SURGICAL PATIENTSThe Lancet, 1989
- Amphotericin B-resistant yeast infection in severely immunocompromised patientsThe American Journal of Medicine, 1988